Skip to content

To study the effect of two drugs karanjadi vati and rosuvastatin tablet in patient with medovridhhi or high Cholesterol level.

A randomized controlled clinical study of karanjadi vati and rosuvastatin tablet in the management of medovridhhi with special reference to hyperlipidaemia.

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2019/08/020739
Enrollment
100
Registered
2019-08-16
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E785- Hyperlipidemia, unspecified

Interventions

Intervention1: KARANJADI VATI: KARANJA CHOORNA BHARANGI CHOORNA SHUDHA GUGGULA Intervention2: Karanjadi Vati: 500mg vati with warm water before meal twice a day Control Intervention1: Rosuvastatin tab

Sponsors

ASHISH KECHE
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1) Patient having Serum LDL Cholesterol Level above 190mg/dl. 2) According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% of CHD whose LDL Cholesterol goals not achieve (>=160mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC). 3) According to NCEP ATP III, Patient having multiple (+2) risk factor with 10 year risk of 10% to 20% of CHD whose LDL Cholesterol goals not achieve (>=130mg/dl) after 12 weeks Therapeutic lifestyle changes (TLC).

Exclusion criteria

Exclusion criteria: 1) Patient with Multiple (+2) risk factor with 10 year risk 10% of CHD, who achieve the goal of LDL Cholesterol ( 2) Patient with Multiple (+2) risk factor with 10 year risk 10% to 20% of CHD, who achieve the goal of LDL Cholesterol ( 3) Pregnant women and lactating mothers. 4) Patients having history of Renal Disease, Liver Disease. 5) Patients having Recently 3 month history of Heart Failure or Stroke. 6) Patients having disorders like Carcinoma etc. anywhere in the body.

Design outcomes

Primary

MeasureTime frame
value of LDL and signs and symptoms of hyperlipidaemia (Medovridhhi).Timepoint: 3 year

Secondary

MeasureTime frame
SAFETY AND EFFICACY OF KARANJADI VATI AND ROSUVASTATIN TABLETTimepoint: 3 years

Countries

India

Contacts

Public ContactASHISH GANGADHARRAO KECHE

R. A. PODAR MEDICAL (AYU) COLLEGE MUMBAI-18

geeta.parulkar@gmail.com8652694332

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026